로딩 중…
지수 로딩 중…
ARS Pharmaceuticals, Inc.
SPRY· NASDAQ· Health Care· Pharmaceuticals, Biotechnology & Life Sciences
$4.11-0.96%
2026-09-18
Financials
Valuation Metrics
ARS Pharmaceuticals, Inc.'s Market Cap is $408M. At end of 2025 it was $1.15B. Ranked #2864 of 3,121 in US market (top 92%), #1271 of 1,463 on NASDAQ (top 87%), #231 of 266 in Pharmaceuticals, Biotechnology & Life Sciences (top 87%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $408M | US#2,864/3,121 Sec#231/266 |
| Revenue | $117M | US#2,675/3,121 Sec#122/266 |
| Net Income | $-215M | US—/3,121 Sec—/266 |
| Total Assets | $249M | US#2,957/3,121 Sec#230/266 |
| Net Assets | $13M | US#2,908/3,121 Sec#239/266 |
| Employees | 163 | US#2,530/3,121 Sec#139/266 |
| Value | ||
| P/B | 32.62x | US#2,859/3,121 Sec#230/266 |
| P/S | 3.49x | US#1,930/3,121 Sec#56/266 |
| FCF Yield | -48.17% | US—/3,121 Sec—/266 |
| Profitability | ||
| ROA | -86.35% | US#3,050/3,121 Sec#249/266 |
| Op. Margin | -184.96% | US#2,767/3,121 Sec#135/266 |
| Revenue Growth | 4.08% | US#1,894/3,121 Sec#120/266 |
| Financial Health | ||
| Debt Ratio | 1894.05% | US#2,848/3,121 Sec#235/266 |
| Total Debt | $172M | US#2,295/3,121 Sec#98/266 |
| FCF | $-197M | US#2,776/3,121 Sec#206/266 |
| Cash | $8M | US#2,997/3,121 Sec#265/266 |
| Current Ratio | 3.48x | US#660/3,121 Sec#173/266 |
| Performance | ||
| 1Y Return | -58.61% | US#2,987/3,121 Sec#248/266 |
| 1M Return | -35.58% | US#3,093/3,121 Sec#263/266 |
| From 52W High | -68.75% | US#3,006/3,121 Sec#242/266 |
| 1Y MDD | -68.53% | US#2,931/3,121 Sec#235/266 |
| Trading | ||
| Volume | 1,723,679 shares | US#890/3,121 Sec#92/266 |
| Trading Value | $7M | US#2,485/3,121 Sec#208/266 |
| Per Share | ||
| EPS | $-2.17 | US—/3,121 Sec—/266 |
| BPS | $0.13 | US#2,797/3,121 Sec#231/266 |
Company Info
ARS Pharmaceuticals, Inc. specializes in creating ARS-1, an innovative intranasal epinephrine spray utilizing advanced absorption technology. This product serves as a crucial intervention for individuals and their households who are susceptible to life-threatening allergic reactions caused by food, pharmaceuticals, or insect stings. Among its offerings is Neffy, a low-dose version of its intranasal epinephrine nasal spray. Established in 2015, the firm operates out of San Diego, California.